Clinical Trial Update: Canakinumab for the Treatment of Postprandial Hypoglycemia [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating canakinumab for postprandial hypoglycemia is currently recruiting at University Hospital Basel.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Postprandial Hypoglycemia

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: University Hospital, Basel, Switzerland | Conditions: Postprandial Hypoglycemia | Phase 3 | Status: RECRUITING